J Cancer 2020; 11(24):7137-7145. doi:10.7150/jca.49213

Research Paper

Clinical Characteristics Correlate With Outcomes of Immunotherapy in Advanced Non-Small Cell Lung Cancer

Lan Huang1,2*, Li Li2*, Yingxu Zhou2*, Zhaoyang Yang2, Meng Wang2, Yina Gao2, Yang Yang2, Fang Yang2, Bao Liu2, Xuan Hong2✉, Gongyan Chen2✉

1. Department of Medical Oncology, Heilongjiang Provincial Hospital, Harbin, China
2. Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China
*These authors contributed equally to this study

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Huang L, Li L, Zhou Y, Yang Z, Wang M, Gao Y, Yang Y, Yang F, Liu B, Hong X, Chen G. Clinical Characteristics Correlate With Outcomes of Immunotherapy in Advanced Non-Small Cell Lung Cancer. J Cancer 2020; 11(24):7137-7145. doi:10.7150/jca.49213. Available from https://www.jcancer.org/v11p7137.htm

File import instruction

Abstract

Considering the existing indicators are not sufficient to predict the patient's response to immune checkpoint inhibitors (ICIs), we conducted this study to evaluate the efficacy and safety of ICIs in advanced non-small cell lung cancer (NSCLC) patients, and to determine prognostic factors of ICIs. In this study, 61 patients diagnosed with advanced NSCLC who underwent ICIs were recruited. The univariate analysis revealed the number of metastatic sites, immune-related adverse events (irAEs) (≥ G2) and best response were significantly associated with both progression-free survival (PFS) and overall survival (OS). Peripheral blood biomarkers, including post-treatment neutrophil-to-lymphocyte ratio (NLR) and CEA levels were also associated with PFS, but not OS. The irAEs (≥ G2), best response and age were confirmed as independent predictors of a prolonged survival by multivariate analysis. The development of irAEs ≥ G2 correlated with a survival benefit in patients with advanced NSCLC (median PFS: 7.1 months vs. 4.6 months, P = 0.013). Thus, we concluded that identifying predictors of benefit from ICIs treatment will help to further extend patient survival in advanced NSCLC.

Keywords: Non-small cell lung cancer, Immune checkpoint inhibitors, Immune-related adverse events (irAEs), Peripheral blood biomarker, clinical outcome